Skip to main content
Erschienen in: Osteoporosis International 3/2014

01.03.2014 | Case Report

Diffuse osteosclerosis in a patient with prostate cancer

verfasst von: N. Üstün, I. Üstün, T. Özgür, N. Atci, F. Aydoğan, A. T. Sümbül, A. D. Turhanoğlu

Erschienen in: Osteoporosis International | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

A 61-year-old man was referred to our outpatient clinic because of severe bilateral upper leg pain for 1 year. On admission, the patient had anemia and a high serum alkaline phosphatase level. Lumbar and femoral neck T-scores were +10.5 and +9.6, respectively. His radius 33 % T-score was −2.8. Plain radiographs of the patient's pelvis, spine, and long bones revealed osteosclerosis. The patient had previously undergone a prostate biopsy, which showed prostate adenocarcinoma (Gleason score 3 + 4). The patient's total and free prostate-specific antigen were very high. According to previous records, the patient did not have anemia, and his serum alkaline phosphatase (ALP) level was normal. An abdominal radiograph taken 2 years earlier revealed a normal spine and pelvic bone. Bone scintigraphy yielded nontypical findings for prostate cancer metastasis. Computed tomography of the patient's thorax and abdomen showed heterogeneous sclerotic areas in all bones consistent with prostate cancer metastasis. A bone marrow biopsy disclosed disseminated carcinomatosis of bone marrow in association with prostate cancer. Clinicians should be aware of the possibility of prostate malignancy as a cause of high bone mineral density (BMD), even in the absence of typical localized findings on plain radiographs.
Literatur
1.
Zurück zum Zitat Saad F, Clarke N, Colombel M (2006) Natural history and treatment of bone complications in prostate cancer. Eur Urol 49:429–440PubMedCrossRef Saad F, Clarke N, Colombel M (2006) Natural history and treatment of bone complications in prostate cancer. Eur Urol 49:429–440PubMedCrossRef
2.
Zurück zum Zitat Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T et al (2012) Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 97:1861–1870PubMedCrossRef Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T et al (2012) Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 97:1861–1870PubMedCrossRef
3.
Zurück zum Zitat Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA et al (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23:2735–2748PubMedCrossRef Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA et al (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23:2735–2748PubMedCrossRef
4.
Zurück zum Zitat Whyte MP (2005) Misinterpretation of osteodensitometry with high bone density: BMD Z > or = + 2.5 is not “normal”. J Clin Densitom 8:1–6PubMedCrossRef Whyte MP (2005) Misinterpretation of osteodensitometry with high bone density: BMD Z > or = + 2.5 is not “normal”. J Clin Densitom 8:1–6PubMedCrossRef
5.
Zurück zum Zitat Gregson CL, Hardcastle SA, Cooper C, Tobias JH (2013) Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology 52:968–985PubMedCentralPubMedCrossRef Gregson CL, Hardcastle SA, Cooper C, Tobias JH (2013) Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology 52:968–985PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Benichou OD, Laredo JD, de Vernejoul MC (2000) Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87–93PubMedCrossRef Benichou OD, Laredo JD, de Vernejoul MC (2000) Type II autosomal dominant osteopetrosis (Albers-Schonberg disease): clinical and radiological manifestations in 42 patients. Bone 26:87–93PubMedCrossRef
7.
Zurück zum Zitat Ihde LL, Forrester DM, Gottsegen CJ, Masih S, Patel DB, Vachon LA et al (2011) Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics 31:1865–1882PubMedCrossRef Ihde LL, Forrester DM, Gottsegen CJ, Masih S, Patel DB, Vachon LA et al (2011) Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics 31:1865–1882PubMedCrossRef
8.
Zurück zum Zitat van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE (2013) Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 28:848–854PubMedCrossRef van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE (2013) Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 28:848–854PubMedCrossRef
9.
Zurück zum Zitat Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C (2009) Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology 253:272–276PubMedCrossRef Wengenroth M, Vasvari G, Federspil PA, Mair J, Schneider P, Stippich C (2009) Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology 253:272–276PubMedCrossRef
10.
Zurück zum Zitat Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543PubMedCrossRef Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M et al (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543PubMedCrossRef
11.
Zurück zum Zitat Semenov MV, He X (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276–38284PubMedCrossRef Semenov MV, He X (2006) LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276–38284PubMedCrossRef
12.
Zurück zum Zitat Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA et al (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513–1521PubMedCrossRef Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA et al (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346:1513–1521PubMedCrossRef
13.
Zurück zum Zitat Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S et al (2006) Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 43:1–11PubMedCrossRef Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S et al (2006) Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet 43:1–11PubMedCrossRef
14.
Zurück zum Zitat Wallace SE, Wilcox WR. Camurati-Engelmann Disease. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews. Seattle WA: University of Washington, Seattle; 1993. Wallace SE, Wilcox WR. Camurati-Engelmann Disease. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews. Seattle WA: University of Washington, Seattle; 1993.
15.
Zurück zum Zitat Hernandez-Cassis C, Vogel CK, Hernandez TP, Econs MJ, Iglesias M, Iglesias A et al (2003) Autosomal dominant hyperostosis/osteosclerosis with high serum alkaline phosphatase activity. J Clin Endocrinol Metab 88:2650–2655PubMedCrossRef Hernandez-Cassis C, Vogel CK, Hernandez TP, Econs MJ, Iglesias M, Iglesias A et al (2003) Autosomal dominant hyperostosis/osteosclerosis with high serum alkaline phosphatase activity. J Clin Endocrinol Metab 88:2650–2655PubMedCrossRef
16.
Zurück zum Zitat Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR et al (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861–2867PubMedCrossRef Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR et al (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861–2867PubMedCrossRef
17.
Zurück zum Zitat Perk H, Yildiz M, Kosar A, Cerci S, Soyupek F, Ozorak A et al (2008) Correlation between BMD and bone scintigraphy in patients with prostate cancer. Urol Oncol 26:250–253PubMedCrossRef Perk H, Yildiz M, Kosar A, Cerci S, Soyupek F, Ozorak A et al (2008) Correlation between BMD and bone scintigraphy in patients with prostate cancer. Urol Oncol 26:250–253PubMedCrossRef
18.
Zurück zum Zitat Chang CH, Tsai CS, Jim YF, Wu HC, Lin CC, Kao A (2003) Lumbar bone mineral density in prostate cancer patients with bone metastases. Endocr Res 29:177–182PubMedCrossRef Chang CH, Tsai CS, Jim YF, Wu HC, Lin CC, Kao A (2003) Lumbar bone mineral density in prostate cancer patients with bone metastases. Endocr Res 29:177–182PubMedCrossRef
19.
Zurück zum Zitat Choueiri MB, Tu SM, Yu-Lee LY, Lin SH (2006) The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25:601–609PubMedCrossRef Choueiri MB, Tu SM, Yu-Lee LY, Lin SH (2006) The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 25:601–609PubMedCrossRef
20.
Zurück zum Zitat Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:1406–1418PubMedCrossRef Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D (2010) Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116:1406–1418PubMedCrossRef
21.
Zurück zum Zitat Brown B, Laorr A, Greenspan A, Stadalnik R (1994) Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med 19:194–196PubMedCrossRef Brown B, Laorr A, Greenspan A, Stadalnik R (1994) Negative bone scintigraphy with diffuse osteoblastic breast carcinoma metastases. Clin Nucl Med 19:194–196PubMedCrossRef
22.
Zurück zum Zitat Morote J, Planas J, Mir MC, Raventos CX, Encabo G, Doll A (2011) 33% radius evaluation to assess bone mineral density in prostate cancer patients. World J Urol 29:815–819PubMedCrossRef Morote J, Planas J, Mir MC, Raventos CX, Encabo G, Doll A (2011) 33% radius evaluation to assess bone mineral density in prostate cancer patients. World J Urol 29:815–819PubMedCrossRef
23.
Zurück zum Zitat Alva A, Hussain M (2013) The changing natural history of metastatic prostate cancer. Cancer J 19:19–24PubMedCrossRef Alva A, Hussain M (2013) The changing natural history of metastatic prostate cancer. Cancer J 19:19–24PubMedCrossRef
Metadaten
Titel
Diffuse osteosclerosis in a patient with prostate cancer
verfasst von
N. Üstün
I. Üstün
T. Özgür
N. Atci
F. Aydoğan
A. T. Sümbül
A. D. Turhanoğlu
Publikationsdatum
01.03.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 3/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2545-9

Weitere Artikel der Ausgabe 3/2014

Osteoporosis International 3/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.